Skandinaviska Enskilda Banken AB publ Has $1.54 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Skandinaviska Enskilda Banken AB publ decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 32.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 32,100 shares of the biopharmaceutical company's stock after selling 15,527 shares during the period. Skandinaviska Enskilda Banken AB publ's holdings in Halozyme Therapeutics were worth $1,541,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter valued at approximately $69,000. RPg Family Wealth Advisory LLC acquired a new position in Halozyme Therapeutics during the 3rd quarter worth $1,886,000. Segall Bryant & Hamill LLC increased its position in shares of Halozyme Therapeutics by 16.3% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company's stock worth $20,330,000 after purchasing an additional 49,856 shares during the last quarter. Retirement Systems of Alabama raised its stake in shares of Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock valued at $22,282,000 after purchasing an additional 74,173 shares in the last quarter. Finally, Shaker Investments LLC OH lifted its position in shares of Halozyme Therapeutics by 12.3% during the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock worth $3,601,000 after purchasing an additional 8,249 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of research firms have commented on HALO. Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Benchmark reaffirmed a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $62.78.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock valued at $1,754,451 in the last ninety days. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Up 1.3 %

NASDAQ:HALO traded up $0.84 during mid-day trading on Friday, reaching $65.16. The stock had a trading volume of 4,000,800 shares, compared to its average volume of 1,326,669. The stock has a market cap of $8.02 billion, a P/E ratio of 19.00, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The business's 50 day moving average is $57.95 and its 200 day moving average is $54.75. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.